18:55 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Feb. 1, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I...
19:06 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Momenta, Global Blood price follow-ons

Momenta raised $200 million Dec. 6 through the sale of 17.4 million shares at $11.50. The price is a 3% premium to Momenta's close of $11.17 on Dec 4. Momenta proposed to raise $150 million...
20:13 , Dec 7, 2018 |  BC Extra  |  Financial News

Momenta, Global Blood price follow-ons

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Global Blood Therapeutics Inc. (NASDAQ:GBT) have each priced follow-ons, raising a total of $350 million. Momenta raised $200 million late Thursday through the sale of 17.4 million shares at $11.50....
18:26 , Nov 30, 2018 |  BC Week In Review  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
00:02 , Nov 29, 2018 |  BC Extra  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
23:52 , Oct 1, 2018 |  BC Extra  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
21:26 , Jul 27, 2018 |  BioCentury  |  Regulation

Biosimilar barriers

A coming showdown over anticompetitive contracting practices, coupled with an impending wave of patent expirations, could result in a wave of biosimilar approvals and launches in the U.S. over the next year, according to biosimilars...
20:47 , Jun 12, 2018 |  BC Extra  |  Politics & Policy

BIO chair outraged by nude dancer party

An industry party held during the BIO annual meeting in Boston has been excoriated by the trade organization for featuring nude or partially clothed female dancers. The trade organization’s chairman called on the party’s sponsors...
22:47 , Apr 24, 2018 |  BC Extra  |  Company News

Amgen considering risk-based Aimovig pricing

On a conference call to discuss 1Q18 earnings call, Amgen Inc. (NASDAQ:AMGN) EVP of Global Commercial Operation Anthony Hooper said the biopharma is "prepared to talk to payers about risk-based contracts with Aimovig." This quarter,...